Xellia Pharmaceuticals
Xellia Pharmaceuticals (Denmark) holds 19 active US FDA Type II Drug Master Files and 4 inactive, has DMF or CEP filings on record for 13 active ingredients, holds 0 active Type IV (excipient) Drug Master Files and is linked to 3 FDA-registered manufacturing sites. 3 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Xellia Pharmaceuticals: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/xellia-pharmaceuticals
Overview
Xellia Pharmaceuticals is a pharmaceutical company headquartered in Copenhagen, Denmark.
Core services & business areas
Active ingredients with DMF or CEP filings
Substances for which Xellia Pharmaceuticals holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Xellia Pharmaceuticals holds 19 active (23 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- DALBAVANCIN HYDROCHLORIDEActive2024-03-27
- VANCOMYCIN WET BASE, NON-STERILEActive2017-07-20
- BACITRACIN ZINC, STERILEActive2014-06-20
- DAPTOMYCIN NON-STERILEActive2013-07-16
- DAPTOMYCINActive2012-12-21
- VANCOMYCIN HYDROCHLORIDEActive2007-06-11
- GRAMICIDIN, USPActive2004-07-12
- TOBRAMYCIN SULPHATE, USP STERILE BULKActive2001-09-17
- TOBRAMYCIN SULPHATE, NON-STERILE BULKActive2000-09-12
- POLYMYXIN B SULFATEActive1999-06-10
- VANCOMYCIN HYDROCHLORIDEActive1998-09-01
- BACITRACIN ZINC USP NON-STERILEActive1998-09-01
- COLISTIMETHATE SODIUM USPActive1998-09-01
- VANCOMYCIN HYDROCHLORIDEActive1998-09-01
- COLISTIN SULFATEActive1998-09-01
- BACITRACIN USP NON-STERILEActive1998-09-01
- AMPHOTERICIN BActive1998-09-01
- BACITRACIN STERILE USPActive1998-09-01
- POLYMYXIN B SULFATE, STERILEActive1998-09-01
- CASPOFUNGIN (ACETATE)Inactive2013-06-14
- MUPIROCIN USP, NON-STERILEInactive2010-05-25
- TOBRAMYCIN SULFATE, USP STERILEInactive2003-08-20
- BACITRACIN ZINC STERILE USPInactive1998-09-01
Excipient Drug Master Files
Xellia Pharmaceuticals holds 0 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.
- N-ACETYL-D-ALANINEInactive2017-09-21
Registered manufacturing sites (3)
Physical sites registered with the US FDA and resolved to Xellia Pharmaceuticals, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
3 FDA enforcement records linked to this company.
- 4832018-05-08
Procedures not in writing, fully followed
- 4832018-05-08
Investigations of discrepancies, failures
- 4832018-05-08
Procedures for sterile drug products
Is this Xellia Pharmaceuticals?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.